RxDoctor Payments Data

Norman Jacobowitz

Family · Manassas, VANPI 1265746317

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by AbbVie at 48.8% of the total. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$54,688in general payments, 2019–2025

Across 483 payments — averaging $113.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$27K
  • Axsome Therapeutics, Inc.$23K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Otsuka America Pharmaceutical, Inc.$599
  • Supernus Pharmaceuticals, Inc.$505
  • Lundbeck LLC$502
  • plus $2K from 13 others

What the payments were for

  • Consulting fees$12,56323%
  • Speaking & faculty fees$29,40054%
  • Travel & lodging$4,2558%
  • Food & beverage$8,42415%
  • Education$470%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,688 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate12$20,050
AuvelityDextromethorphan Hbr/Bupropion15$16,128
Quetiapine Fumarate19$1,733
Ziprasidone Hcl12$1,355
Paliperidone ErPaliperidone12$1,273
Divalproex Sodium ErDivalproex Sodium12$1,091
Hydroxyzine Hcl21$826
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$794
Mirtazapine25$711
Gabapentin27$430
Escitalopram Oxalate20$334
Buspirone Hcl17$318
Paroxetine Hcl15$299
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$249
Bupropion XlBupropion Hcl13$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,408$20,05012 claims
Axsome Therapeutics, Inc.Auvelity$23,332$16,12815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Manassas

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →